AVMXY Projected Dividend Yield

Avita Medical Ltd ( OTCBB : AVMXY )

Avita Medical is engaged in the commercialisation of its regenerative product. Co. develops and distributes regenerative products for the treatment of a range of wounds, scars and skin defects. Co.'s patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Co.'s primary product, ReCell®, is used in the treatment of a variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the U.S., ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway.

20 YEAR PERFORMANCE RESULTS